Business Club December 21
The core message: The medical income of anti-infective drugs in China is about 74 billion yuan annually, and the average growth rate of the industry in the past 5 years has reached 24.5%. In 2009, the scale of China's antibiotic market reached 66.6 billion yuan. According to this calculation, the antibiotic market size this year will be expected to exceed 80 billion yuan.
[Editor's note] The scale of the antibiotic market is expected to benefit the related stocks. It is recommended to first focus on the major potent antibiotic manufacturers Zhejiang Medicine (600216) (vancomycin), Health Yuan (600380) and Hisun Pharmaceutical (600267) (carbon Penicillins and Colistin production companies have been trading opportunities for Lianhua Pharmaceutical. The antibiotic industry will standardize the use of drugs in the future, and product abuse should be controlled. The industry concentration level is expected to increase substantially in the future. It is recommended to pay close attention to antibiotics leading companies Lukang Pharmaceutical (600789), North China Pharmaceutical (600812) and Harbin Pharmaceutical (600664).
Antibiotic market is expected to exceed 800 billion
Recently, Wu Huifang, the chief researcher of Health Network, briefed the reporter on the “Antibiotic Industry Competition Analysis Report 2011†organized by Beijing Oriental Bit Technology Co., Ltd. (Health Network). The medical income of anti-infective drugs in China is about 74 billion yuan per year. In the past five years, the average growth rate of the industry reached 24.5%. In 2009, the scale of China's antibiotic market reached 66.6 billion yuan. According to this calculation, the antibiotic market size this year will be expected to exceed 80 billion yuan.
The report will take the antibiotic industry chain as the theme, under the background of market and industrialization technology, systematically analyze the upstream and downstream supply and demand relationship and interest relationship of the antibiotic industry chain, and thus make a judgment on the competition situation and trend of the antibiotic industry.
According to reports, the main competitive products of the antibiotic industry are penicillin, cephalosporins, erythromycin and so on. At present, major companies in the industry have relevant plans for increase and expansion. The Dengyan project of Xinghu Science and Technology, the cephalosporin products of North China Pharmaceuticals, and the intermediate 7ACA project, and azithromycin of the Shijiazhuang Group all announced expansion plans in 2010, and all of them passed the environmental assessment publicity during the year.
When talking about the most concerned antibiotic export situation, Wang Zhong, the manager of Aosung’s business department, told reporters that at present, exports of intermediates, APIs and preparations are the most popular in the country. Among them, stone medicine, China medicine, and Hisun Pharmaceutical Industry and Huahai Pharmaceuticals are leaders in terms of capital, R&D, certification, and international marketing. However, he also reminded that to achieve exports, China's pharmaceutical companies are also facing risks such as laws, policies, and exchange rates.
It is understood that the status and role of the antibiotic industry in the global pharmaceutical industry chain play a decisive role. Antibiotics are both the largest therapeutic drug and the most sensitive drug category related to human diseases and health. It not only involves the most extensive industrial chain, but also has complicated and changing market influence factors. Today's market competition has risen from simple product competition to industry competition triggered by interest relationships in the industrial chain.
The core message: The medical income of anti-infective drugs in China is about 74 billion yuan annually, and the average growth rate of the industry in the past 5 years has reached 24.5%. In 2009, the scale of China's antibiotic market reached 66.6 billion yuan. According to this calculation, the antibiotic market size this year will be expected to exceed 80 billion yuan.
[Editor's note] The scale of the antibiotic market is expected to benefit the related stocks. It is recommended to first focus on the major potent antibiotic manufacturers Zhejiang Medicine (600216) (vancomycin), Health Yuan (600380) and Hisun Pharmaceutical (600267) (carbon Penicillins and Colistin production companies have been trading opportunities for Lianhua Pharmaceutical. The antibiotic industry will standardize the use of drugs in the future, and product abuse should be controlled. The industry concentration level is expected to increase substantially in the future. It is recommended to pay close attention to antibiotics leading companies Lukang Pharmaceutical (600789), North China Pharmaceutical (600812) and Harbin Pharmaceutical (600664).
Antibiotic market is expected to exceed 800 billion
Recently, Wu Huifang, the chief researcher of Health Network, briefed the reporter on the “Antibiotic Industry Competition Analysis Report 2011†organized by Beijing Oriental Bit Technology Co., Ltd. (Health Network). The medical income of anti-infective drugs in China is about 74 billion yuan per year. In the past five years, the average growth rate of the industry reached 24.5%. In 2009, the scale of China's antibiotic market reached 66.6 billion yuan. According to this calculation, the antibiotic market size this year will be expected to exceed 80 billion yuan.
The report will take the antibiotic industry chain as the theme, under the background of market and industrialization technology, systematically analyze the upstream and downstream supply and demand relationship and interest relationship of the antibiotic industry chain, and thus make a judgment on the competition situation and trend of the antibiotic industry.
According to reports, the main competitive products of the antibiotic industry are penicillin, cephalosporins, erythromycin and so on. At present, major companies in the industry have relevant plans for increase and expansion. The Dengyan project of Xinghu Science and Technology, the cephalosporin products of North China Pharmaceuticals, and the intermediate 7ACA project, and azithromycin of the Shijiazhuang Group all announced expansion plans in 2010, and all of them passed the environmental assessment publicity during the year.
When talking about the most concerned antibiotic export situation, Wang Zhong, the manager of Aosung’s business department, told reporters that at present, exports of intermediates, APIs and preparations are the most popular in the country. Among them, stone medicine, China medicine, and Hisun Pharmaceutical Industry and Huahai Pharmaceuticals are leaders in terms of capital, R&D, certification, and international marketing. However, he also reminded that to achieve exports, China's pharmaceutical companies are also facing risks such as laws, policies, and exchange rates.
It is understood that the status and role of the antibiotic industry in the global pharmaceutical industry chain play a decisive role. Antibiotics are both the largest therapeutic drug and the most sensitive drug category related to human diseases and health. It not only involves the most extensive industrial chain, but also has complicated and changing market influence factors. Today's market competition has risen from simple product competition to industry competition triggered by interest relationships in the industrial chain.
Peeled Onions,Fresh Peeled Onions,Peeled Fresh Red Onion,Fresh Yellow Onion Peeled
Yirun Agricultural Cooperative , https://www.yiruncn.com